Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)

Authors

Sasha Stanton, ProvidenceFollow
See all authors in comments

Document Type

Presentation

Publication Date

12-6-2022

Keywords

oregon; portland; chiles

Clinical Institute

Cancer

Clinical Institute

Women & Children

Department

Oncology

Comments

Stanton SE, MacDonald LD, Fiset S, Mellinger S, Moxon N, Hirsch H, Kelly TL, Young KH, Page DB. SABCS Annual Meeting; December 6-10; San Antonio, TX. 2022;40(16_suppl): TPS1119. doi: 10.1200/JCO.2022.40.16_suppl.TPS1119.

Recommended Citation

Stanton, Sasha and See all authors in comments, "Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)" (2022). Articles, Abstracts, and Reports. 6995.
https://digitalcommons.providence.org/publications/6995